Business context and reporting period
InflaRx N.V. filed an annual Form 20-F for the fiscal year ended December 31, 2022—not a standalone 2022 fourth-quarter report. The Dutch-incorporated, Germany-based company is a clinical-stage biopharmaceutical developer focused on C5a/C5aR inhibitors. Its lead candidate, vilobelimab, is being developed for several inflammatory conditions. Financial statements are prepared in euros under IFRS as issued by the IASB.
Financial performance, cash flow and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | €37.5 million | €35.7 million |
| General and administrative expense | €14.9 million | €12.0 million |
| Government-grant income, primarily COVID-19 program | €20.1 million | €0.05 million |
| Net loss | €29.5 million | €45.6 million |
| Basic and diluted loss per share | €0.67 | €1.10 |
| Net cash used in operating activities | €33.7 million | €39.9 million |
| Cash and cash equivalents at year-end | €16.3 million | €26.2 million |
| Marketable securities at year-end | €67.2 million | €83.7 million |
Loss narrowed year over year mainly because of €20.1 million of grant income, not product sales. Operating expenses rose by €4.7 million combined; R&D costs reflected clinical and manufacturing activity, while G&A increases included share-based compensation, consulting and legal costs, and directors’ and officers’ insurance. The company reported a positive net financial result of approximately €2.8 million, including foreign-exchange gains and interest income. No income tax expense was recorded.
Total assets were €102.4 million and equity was €88.3 million at year-end. The company reported no borrowings; liabilities were principally trade and other payables, government-grant liabilities and lease liabilities. Lease liabilities totaled €1.36 million. Current assets were €97.4 million versus current liabilities of €13.0 million. Management said existing cash, cash equivalents and financial assets were expected to fund its current business plan for at least 24 months from December 31, 2022, while also warning that circumstances could accelerate cash use and additional financing would be needed to advance development.
Operating cash use improved from 2021, while investing activities provided €19.4 million of net cash, largely reflecting maturities and purchases of securities. Financing activities provided €1.9 million, chiefly from the €2.3 million Staidson share issuance net of costs. Contractual obligations at year-end totaled €24.2 million, including €22.8 million of CRO and other operating commitments, most due within one year.
Material changes versus the prior comparable period
- Net loss declined by €16.1 million, primarily due to recognition of German government grant income; operating expenses increased from €47.7 million to €52.4 million.
- Operating cash use decreased by €6.2 million. Cash and cash equivalents fell by €10.0 million, and marketable securities by €16.5 million, compared with year-end 2021.
- R&D expense increased €1.8 million; G&A expense increased €2.9 million. Grant income recognized in 2022 was €20.1 million, compared with €0.05 million of other income in 2021.
- Shares outstanding increased to 44,703,763 from 44,203,763, including 500,000 shares sold to Staidson at $5.00 per share. The 2021 public offering had raised $75.0 million gross.
Outlook, management commentary and key risks
- Development and regulatory milestones: The company reported submitting an FDA emergency use authorization application for vilobelimab in critically ill, mechanically ventilated COVID-19 patients in September 2022; the filing states there was no set FDA decision timeline. The Phase III PANAMO trial showed a 23.9% relative reduction in 28-day mortality, but the primary analysis was not statistically significant (p=0.094). A prespecified Western European subgroup showed a 43% relative reduction (p=0.014).
- Pipeline: A Phase III trial protocol for ulcerative pyoderma gangrenosum (PG) was submitted to the FDA; the company expected enrollment to begin in mid-2023. Vilobelimab’s Phase II cSCC study continued, with initial data expected in the first half of 2024. The HS Phase III program was halted after conflicting FDA feedback, and the company was evaluating next steps. Further AAV development was also under review, including potential partnering. INF904 entered Phase I in November 2022; IFX002 remained preclinical.
- Grant and manufacturing: The German government grant was reduced from a maximum €43.7 million to €41.4 million and reimburses 80% of specified eligible costs through June 30, 2023. €25.6 million had been received by year-end; €15.9 million remained available subject to eligible spending and grant conditions. The company was working to validate manufacturing and transfer fill-and-finish to Germany, while relying on third-party manufacturers, including a supplier in China.
- Funding and operating risks: The company has never generated product revenue, has a €243.5 million accumulated deficit, expects continued losses, and may need additional capital. Financing could dilute shareholders or require debt, partnerships or licensing on unfavorable terms. The reported runway is management’s estimate and depends on development costs, trial timing, grant eligibility and other assumptions.
- Other material risks: Clinical and regulatory outcomes remain uncertain; patient recruitment, manufacturing scale-up and third-party performance could delay programs. The company is exposed to U.S. dollar/euro movements and has no hedging arrangements. It believed it was likely a passive foreign investment company (PFIC) for U.S. tax purposes in 2020–2022. Grant terms may permit government rights in funded intellectual property and may require repayment or revocation in specified circumstances.
- Governance and audit: Management and Ernst & Young reported effective internal control over financial reporting, and the auditor issued unqualified opinions on the financial statements and internal controls. Ernst & Young identified estimation of clinical-trial and contracted-manufacturing expenses as a critical audit matter. The company lost emerging-growth-company status at year-end 2022 and began auditor attestation under Section 404(b).
Important facts for investors to verify
- Check subsequent FDA and other regulatory decisions on the COVID-19 EUA application, and the status and results of the PG Phase III and cSCC programs.
- Reconcile the cash, marketable-securities and total financial-assets disclosures: the filing reports €16.3 million of cash and €67.2 million of marketable securities, with some narrative passages using differing figures.
- Assess the assumptions behind management’s at-least-24-month runway, the expected cash burn, the remaining grant availability and the €24.2 million of contractual commitments.
- Review manufacturing transfer and validation progress, including supply concentration and exposure to China-based production.
- Review dilution and related-party terms, including the Staidson share purchase, its conditional additional-share option, and outstanding equity awards.
- For U.S. investors, confirm PFIC status and related filing or election requirements with a tax adviser.